Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
McKesson
Moodys
Baxter
Boehringer Ingelheim

Last Updated: September 30, 2022

Investigational Drug Information for PF-06882961


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug PF-06882961?

PF-06882961 is an investigational drug.

There have been 15 clinical trials for PF-06882961. The most recent clinical trial was a Phase 2 trial, which was initiated on January 6th 2021.

The most common disease conditions in clinical trials are Diabetes Mellitus, Diabetes Mellitus, Type 2, and Obesity. The leading clinical trial sponsors are Pfizer and [disabled in preview].

There are four US patents protecting this investigational drug and fifty-four international patents.

Recent Clinical Trials for PF-06882961
TitleSponsorPhase
STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTSPfizerPhase 1
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes MellitusPfizerPhase 1
A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise HealthyPfizerPhase 1

See all PF-06882961 clinical trials

Clinical Trial Summary for PF-06882961

Top disease conditions for PF-06882961
Top clinical trial sponsors for PF-06882961

See all PF-06882961 clinical trials

US Patents for PF-06882961

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PF-06882961 See Plans and Pricing GLP-1 receptor agonists and uses thereof Pfizer Inc. (New York, NY) See Plans and Pricing
PF-06882961 See Plans and Pricing GLP-1 receptor agonists and uses thereof Pfizer Inc. (New York, NY) See Plans and Pricing
PF-06882961 See Plans and Pricing GLP-1R agonists and uses thereof QILU REGOR THERAPEUTICS INC. (Shanghai, CN) See Plans and Pricing
PF-06882961 See Plans and Pricing GLP-1 receptor agonists and uses thereof Pfizer Inc. (New York, NY) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PF-06882961

Drugname Country Document Number Estimated Expiration Related US Patent
PF-06882961 Argentina AR110387 2036-12-16 See Plans and Pricing
PF-06882961 Australia AU2017374860 2036-12-16 See Plans and Pricing
PF-06882961 Brazil BR112019012211 2036-12-16 See Plans and Pricing
PF-06882961 Canada CA2988721 2036-12-16 See Plans and Pricing
PF-06882961 Chile CL2019001651 2036-12-16 See Plans and Pricing
PF-06882961 China CN110325530 2036-12-16 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
McKesson
Moodys
Baxter
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.